HRQOL ‐ not measured · Participants with rosacea
The review found no eligible studies for this question.
1 finding from 1 review
HRQOL ‐ not measured · Participants with rosacea
The review found no eligible studies for this question.
1 finding from 1 review
Participant‐assessed improvement in rosacea severity ‐ not measured · Participants with rosacea
The review found no eligible studies for this question.
1 finding from 1 review
Proportion of participants with adverse event · Participants with rosacea
Doxycycline 40 mg + metronidazole 1% gel may leads to lower proportion of participants with adverse event compared with doxycycline 100 mg + metronidazole 1% gel (low certainty).
1 finding from 1 review
Physician‐assessed improvement in rosacea severity · Participants with rosacea
1 finding from 1 review
Assessment of erythema or telangiectasia · Participants with rosacea
1 finding from 1 review
Lesion count · Participants with rosacea
1 finding from 1 review
Time needed until improvement of the skin lesions · Participants with rosacea
1 finding from 1 review
Duration of remission ‐ not measured · Participants with rosacea
The review found no eligible studies for this question.
1 finding from 1 review
HRQOL ‐ not measured · Participants with rosacea
The review found no eligible studies for this question.
1 finding from 1 review
Participant‐assessed improvement in rosacea severity · Participants with rosacea
Doxycycline 40 mg + azelaic acid gel showed no clear difference in participant‐assessed improvement in rosacea severity Excellent… compared with doxycycline 40 mg + metronidazole gel (high certainty).
1 finding from 1 review
Proportion of participants with adverse event · Participants with rosacea
Doxycycline 40 mg + azelaic acid gel showed no clear difference in proportion of participants with adverse event compared with doxycycline 40 mg + metronidazole gel (high certainty).
1 finding from 1 review
Change in DLQI score (LOCF) · participants with hidradenitis suppurativa
2 findings from 1 review
Treatment discontinuation · participants with hidradenitis suppurativa
Adalimumab every other week showed no clear difference in frequency of treatment discontinuation compared with placebo (high certainty).
1 finding from 1 review
Proportion of participants with infectious adverse effects · participants with hidradenitis suppurativa
Adalimumab every other week showed no clear difference in proportion of participants with infectious adverse effects compared with placebo (high certainty).
1 finding from 1 review
Change in Pain VAS · participants with hidradenitis suppurativa
1 finding from 1 review
Proportion with improvement in pain · participants with hidradenitis suppurativa
Adalimumab every other week showed no clear difference in proportion with improvement in pain compared with placebo (moderate certainty).
1 finding from 1 review
Change in Sartorius scale score (LOCF) · participants with hidradenitis suppurativa
1 finding from 1 review
At least 50% decrease in HS Severity Index · participants with hidradenitis suppurativa
Infliximab showed no clear difference in at least 50% decrease in HS Severity Index compared with placebo (moderate certainty).
1 finding from 1 review
Physician Global Assessment (Thongprasom score) · participants with hidradenitis suppurativa
Infliximab probably leads to higher physician global assessment compared with placebo (moderate certainty).
1 finding from 1 review